| Patents for C12N - Micro-organisms or enzymes; Compositions thereof; Propagating, preserving, or maintaining micro-organisms; Mutation or genetic engineering; Culture media (9,992) |
|---|
| 02/10/2005 | US20050033029 Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses |
| 02/10/2005 | US20050032732 DNA vaccine expressing HA1 of equine-2 influenza virus |
| 02/10/2005 | US20050032217 Transforming lymphocytes with vector comprising gene sequences which code cytolethal distending toxin (cdt), leukotoxins and heat shock protein and generating regulatory cell which can be used to treat and/or prevent transplant rejection, autoimmune and inflammatory diseases; immunotherapy |
| 02/10/2005 | US20050032174 Multimeric protein for use in the treatment and prevention of infection and bleeding disorders |
| 02/10/2005 | US20050032170 Expression vector comprising nucleotide sequences coding native sequence-4 (NS4) for use in identifying modulators for treatment and prevention of obesity, cachexia and anorexia |
| 02/10/2005 | US20050032166 Expression vector comprising nucleotide sequences coding adipokine binding protein for use in treatment and prevention of diabetes, obesity, inflammation, cardiovascular and metabolic disorders |
| 02/10/2005 | US20050032146 Tssk4: a human testis specific serine/threonine kinase |
| 02/10/2005 | US20050032068 Oligomers hybridize with each other, one of which includes peptide nucleic acid or mimic, a morpholino nucleic acid, hexose sugar with amide linkage, cyclohexenyl nucleic acid or an acyclic backbone modification; gene expression inhibition |
| 02/10/2005 | US20050031630 Immunogen (antibody determinant, lipid, peptide, and/or carbohydrate) derived from virus/cancer cell with mast cell membrane activator; microbiocides; wound healing agents; reduced scarring |
| 02/10/2005 | CA2537899A1 Tissue-specific targeting of therapeutic and imaging agents to caveolae |
| 02/10/2005 | CA2534639A1 Anti-cd19 antibodies |
| 02/10/2005 | CA2534441A1 Arrays, methods and kits for preparation and use of syntenic genomic arrays for diagnostics and toxicology |
| 02/10/2005 | CA2534432A1 Methods for treating diabetes and related disorders using pde10a inhibitors |
| 02/10/2005 | CA2534360A1 Methods for expression and purification of immunotoxins |
| 02/10/2005 | CA2533941A1 Novel nucleic acids from sesame plants |
| 02/10/2005 | CA2533936A1 Metabolically engineered bacterial strains having enhanced 2-keto-d-gluconate accumulation |
| 02/10/2005 | CA2533305A1 Methods for amplifying polymeric nucleic acids |
| 02/10/2005 | CA2530630A1 Systems and methods for separating and concentrating regenerative cells from tissue |
| 02/10/2005 | CA2530172A1 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| 02/10/2005 | CA2520768A1 Methods of identifying optimal variants of peptide epitopes |
| 02/09/2005 | EP1503745A2 15625 receptor, a novel g-protein coupled receptor |
| 02/09/2005 | EP1009805A4 TRANSGENIC PLANTS OF ALTERED MORPHOLOGY AND THE ISOLATED $i(ARABIDOPSIS THALIANA) ENDO-1,4-$g(b)-GLUCANASE GENE, PROMOTER AND PROTEIN |
| 02/09/2005 | CN1188518C Enzyme stabilization by cationic surfactants |
| 02/08/2005 | US6852322 Surface proteins of Leptospira |
| 02/03/2005 | WO2005010169A2 High throughput or capillary-based screening for a bioactivity or biomolecule |
| 02/03/2005 | WO2005010168A2 Method and system for detecting chloramphenicol |
| 02/03/2005 | WO2005010166A2 P450 oxygenases and methods of use |
| 02/03/2005 | WO2005010165A2 Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof |
| 02/03/2005 | WO2005010163A2 Compositions and methods for immunotherapy of human immunotherapy of human immunodeficiency virus (hiv) |
| 02/03/2005 | WO2005010162A2 Automated cell culture system and process |
| 02/03/2005 | WO2005010161A2 Device and method to facilitate directed delivery and electroporation |
| 02/03/2005 | WO2005010160A2 Liquid crystals with reduced toxicity and applications thereof |
| 02/03/2005 | WO2005010159A2 Rolling circle amplification of micro-rna samples |
| 02/03/2005 | WO2005010158A2 Ex vivo methods and compositions for administering a rnai agent to a subject |
| 02/03/2005 | WO2005010157A2 Use of pleiotrophin in the diagnosis, treatment and prevention of disease |
| 02/03/2005 | WO2005010156A2 Genes encoding carotenoid compounds |
| 02/03/2005 | WO2005010155A2 Methods of decoupling reaction scale and protein synthesis yield in batch mode |
| 02/03/2005 | WO2005010154A2 7 and 8 membered heterocyclic cyclopentyl benzylamide modulators of chemokine receptor activity |
| 02/03/2005 | WO2005010152A2 Human mast cell-expressed membrane protein |
| 02/03/2005 | WO2005010151A2 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| 02/03/2005 | WO2005010150A2 Method for in vitro selection of 2’-substituted nucleic acids |
| 02/03/2005 | WO2005010149A2 Subgroup b adenoviral vectors for treating disease |
| 02/03/2005 | WO2005010148A2 Marks as modifiers of the pten pathway and methods of use |
| 02/03/2005 | WO2005010147A2 Device and method for contacting pocoliter volumes of fluids |
| 02/03/2005 | WO2005010145A2 Method and compositions for detection and enumeration of genetic variations |
| 02/03/2005 | WO2005010143A2 Methods of treatment and disgnosis using modulators of virus-induced cellular gene sequences |
| 02/03/2005 | WO2005010142A2 Plant centromere compositions |
| 02/03/2005 | WO2005010141A2 Compositions for purifying and crystallizing molecules of interest |
| 02/03/2005 | WO2004094594A3 Non-human animal model for graft-versus-host disease |
| 02/03/2005 | WO2004081175A3 Methods and compositions for purification of nucleic acid from a host cell |
| 02/03/2005 | WO2004065541A3 Method and apparatus for treating bodily tissues with medicinal substance |
| 02/03/2005 | WO2004038005A3 Methods of identifying reduced internalization transmembrane receptor agonists |
| 02/03/2005 | WO2003095624B1 Liver inflammation predictive genes |
| 02/03/2005 | WO2003040317A8 Lung cancer therapeutics and diagnostics |
| 02/03/2005 | US20050027113 Compositions and methods relating to the daptomycin biosynthetic gene cluster |
| 02/03/2005 | US20050027109 Preparing genetically engineered therapeutic protein fusion comprised of antibody constant region for use in treatment of metabolic disorders |
| 02/03/2005 | US20050027064 Charge-dynamic polymers and delivery of anionic compounds |
| 02/03/2005 | US20050026987 CBI analogues of the duocarmycins and CC-1065 |
| 02/03/2005 | US20050026861 Modified dinucleotides for reduce or improve immunostimulatory; genetic vaccines; cancer vaccines |
| 02/03/2005 | US20050026286 Methods and compositions for selective RNAi mediated inhibition of gene expression in mammal cells |
| 02/03/2005 | US20050026278 RNA interference mediating small RNA molecules |
| 02/03/2005 | US20050026198 Method of selecting an active oligonucleotide predictive model |
| 02/03/2005 | US20050026191 Nucleotide sequences coding interferon-inducible proteins in fibroblasts for use in diagnosis, prevention and treatment of cell proliferative, nervous system, glandular and inflammatory diseases |
| 02/03/2005 | US20050026174 Alternative heterocycles for DNA recognition |
| 02/03/2005 | US20050026161 Detecting non-nucleic acid analyte present in sample: comprising, contacting sample with non-nucleic acid analyte reporter conjugate, allow complex to form, elute and monitor for nucleic acid marker in sample; immunodiagnostics |
| 02/03/2005 | CA2532809A1 Plant centromere compositions |
| 02/03/2005 | CA2532754A1 Automated cell culture system and process |
| 02/03/2005 | CA2532102A1 7 and 8 membered heterocyclic cyclopentyl benzylamide modulators of chemokine receptor activity |
| 02/03/2005 | CA2532084A1 Methods of treatment and diagnosis using modulators of virus-induced cellular gene sequences |
| 02/03/2005 | CA2531493A1 Device and method to facilitate directed delivery and electroporation |
| 02/03/2005 | CA2531492A1 Compositions for purifying and crystallizing molecules of interest |
| 02/03/2005 | CA2531105A1 Method and compositions for detection and enumeration of genetic variations |
| 02/03/2005 | CA2531073A1 Human mast cell-expressed membrane protein |
| 02/03/2005 | CA2530285A1 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| 02/03/2005 | CA2528043A1 Marks as modifiers of the pten pathway and methods of use |
| 02/03/2005 | CA2527557A1 Genes encoding carotenoid compounds |
| 02/03/2005 | CA2527369A1 Subgroup b adenoviral vectors for treating disease |
| 02/03/2005 | CA2526814A1 Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof |
| 02/02/2005 | EP1502104A2 Comparative field analysis (comfa) utilizing topomeric alignment of molecular fragments |
| 02/02/2005 | EP1501948A1 A dna enzyme to inhibit plasminogen activator inhibitor-1 |
| 02/02/2005 | EP1501369A2 Non-affinity purification of proteins |
| 02/02/2005 | EP1501351A2 Short fragment homologous replacement to provide bse resistant cattle |
| 02/02/2005 | CN1575338A Bv8 nucleic acids and polypeptides with mitogenic activity |
| 02/01/2005 | US6849720 Monoclonal antibodies to the human LDL receptor, their production and use |
| 01/27/2005 | WO2005007832A2 System for external control of oncolytic virus replication |
| 01/27/2005 | WO2005007831A2 Compositions of protein mimetics and methods of using same against hiv-1, sars-cov and the like |
| 01/27/2005 | WO2005007830A2 Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| 01/27/2005 | WO2005007829A2 Materials and methods for the modulation of cyclin-dependent kinase inhibitor-like polypeptides in maize |
| 01/27/2005 | WO2005007828A2 Regulation of hif protein levels via deubiquitination pathways |
| 01/27/2005 | WO2005007827A2 Avian adeno-associated virus vector |
| 01/27/2005 | WO2005007826A2 Production of aromatic carotenoids in gram negative bacteria |
| 01/27/2005 | WO2005007825A2 Modulation of aminopeptidase n expression |
| 01/27/2005 | WO2005007824A2 Mutants of vaccinia virus as oncolytic agents |
| 01/27/2005 | WO2005007823A2 Compositions, kits, and methods for stimulation of homologous recombination |
| 01/27/2005 | WO2005007822A2 Method for assaying protein-protein interaction |
| 01/27/2005 | WO2005007821A2 Tertiary structures of ica-1/lfa-1 modulators |
| 01/27/2005 | WO2005007820A2 Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity |
| 01/27/2005 | WO2005007819A2 Charge-dynamic polymers and delivery of anionic compounds |
| 01/27/2005 | WO2005007817A2 Hexameric porphobilinogen synthase as a target for the development of antibiotics and herbicides |
| 01/27/2005 | WO2005007816A2 Compositions and methods for identifying an individual organism based on single nucleotide polymorphisms |